TenNor Therapeutics (Suzhou) Limited (HKG:6872)

Market Cap	10.45B
Revenue (ttm)	n/a
Net Income	-170.53M
EPS	-4.28
Shares Out	51.75M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	82,300
Open	202.00
Previous Close	203.60
Day's Range	197.90 - 208.00
52-Week Range	75.70 - 256.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About HKG:6872

TenNor Therapeutics (Suzhou) Limited engages in discovery, development and commercialization of differentiated therapies for diseases associated with bacterial infections and bacterial metabolism. The company's offerings include drug production and medical research and experimental development, with a pipeline of products such as Rifasutenizole (TNP-2198) for treatment of Helicobacter pylori infection; Rifaquizinone (TNP-2092) injection for treatment of Periprosthetic Joint Infection (PJI), Acute Bacterial Skin and Skin Structure Infections (AB...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Country: China
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6872

Financial Performance

Financial numbers in CNY